Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986318 in healthy participants
NCT04082741Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986318 in Nonalcoholic steatohepatitis (NASH) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of non-serious adverse events (AEs) up to 30 days, Incidence of Serious Adverse Events (SAE) up to 30 days and 11 more. Planned start Jul 2019; status: withdrawn.
02
Drugs
BMS-986318
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04082741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082741.